

**NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE**

**Single Technology Appraisal**

**Equality impact assessment – Scoping**

**Eplontersen for treating hereditary transthyretin amyloidosis [ID6337]**

The impact on equality has been assessed during this evaluation according to the principles of the NICE Equality scheme.

- |   |
|---|
| 1. Have any potential equality issues been identified during the scoping process (draft scope consultation and scoping workshop discussion), and, if so, what are they? |
|---|

It was raised during the scope consultation that the Val122Ile variant of transthyretin amyloid cardiomyopathy (ATTR-CM) is most common in people with African or Caribbean family background and that excluding people who have ATTR-CM from the appraisal, at this time, raises equality issues on both racial and age grounds.
---

- |   |
|---|
| 2. What is the preliminary view as to what extent these potential equality issues need addressing by the committee? |
|---|

The population of the scope is ‘adults with hereditary ATTR amyloidosis who have stage 1 or stage 2 polyneuropathy’. NICE can only appraise treatments within their marketing authorisation. Although currently unknown, based on the NEURO-TTRansform trial population, it is not expected that people with cardiomyopathy will be included in the marketing authorisation. This was reflected in the scope population. Therefore, it is not considered to be a potential equality issue.
--

- |  |
|--|
| 3. Has any change to the draft scope been agreed to highlight potential equality issues? |
|--|

No.
-----

4. Have any additional stakeholders related to potential equality issues been identified during the scoping process, and, if so, have changes to the stakeholder list been made?

No.

**Approved by Associate Director (name):** ...Linda Landells

**Date:** 8 January 2024